Severe SARS-CoV-2 infection treated with the mannose binding lectin associated serine protease 2 (MASP2) inhibitor Narsoplimab
Date
2021-01-01
Embargo Lift Date
Department
Committee Members
Degree
Degree Year
Department
Grantor
Journal Title
Journal ISSN
Volume Title
Found At
ProBiologists
Can't use the file because of accessibility barriers? Contact us with the title of the item, permanent link, and specifics of your accommodation need.
Abstract
In SARS-CoV-2 infection, increased inflammation, complement activation, and excessive clotting are responsible for morbidity and mortality. Recent reports suggest that mannose binding lectin (MBL) and mannose-associated serine protease 2 (MASP2) lies at the intersection of these pathways. Consistent with this concept, we observed that the SARS-CoV-2 spike protein binds MBL-MASP1/2 complex in human serum. We therefore suggested treating a severely ill, ventilated SARS-CoV-2 patient in whom all other treatments had failed with the anti-MASP2 antibody Narsoplimab. Following a 4-week course of Narsoplimab, the patient made a near complete recovery, supporting the utility of MASP2 inhibition for treating hospitalized SARS-CoV-2 patients.
Description
Keywords
item.page.description.tableofcontents
item.page.relation.haspart
Cite As
Knierman MD, Gelfanova V, Zlatniski NA, Mullen JH, Siegel RW, Konrad RJ. Severe SARS-CoV-2 infection treated with the mannose binding lectin associated serine protease 2 (MASP2) inhibitor Narsoplimab. J Allergy Infect Dis 2021; 2(1):24-28.
ISSN
Publisher
Series/Report
Sponsorship
Major
Extent
Identifier
Relation
Journal
Journal of Allergy and Infectious Diseases
Source
Alternative Title
Type
Article